In FRDA, Fxn levels are already at a critically low level, so the discovery that this level can be further reduced due to increased mitochondrial iron and ROS may provide additional guidance on therapeutic interventions to delay disease progression. The gene discussed is FXN; the disease is Friedreich ataxia.